161 First Street
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those directly impacted by the disease, Solid aims to be the center of excellence across the entire DMD disease spectrum, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease Modifying Therapies, Disease Understanding and Assistive Devices.
Founder and CEO: Ilan Ganot
Founder, Patient Advocacy: Annie Ganot
CMO: Jorge A. Quiroz, M.D.
SVP Operations: Alvaro Amorrortu
Please click here for Solid Biosciences' technology.